Bardy Diagnostics, Inc.

23 articles about Bardy Diagnostics, Inc.

• Hillrom Comments on Recent Novitas Reimbursement Update

  4/11/2021

  Hillrom previously announced its intent to acquire Bardy Diagnostics, Inc. On April 10, 2021, the Medicare Administrative Contractor, Novitas Solutions, published updated reimbursement rates applicable to the Current Procedural Terminology codes 93241, 93243, 93245 and 93247 for the extended Holter cardiac monitoring category applicable to all of BardyDx's products and services.

• Hillrom Comments On Novitas Reimbursement Decision

  2/1/2021

  Hillrom previously announced its intention to acquire Bardy Diagnostics, Inc., an innovator in digital health and a leading provider of ambulatory cardiac monitoring.

• Bardy Diagnostics® Announces Appointment of Kevin Hykes as President and Chief Executive Officer

  9/8/2020

   Bardy Diagnostics, Inc., ("BardyDx"), a leading developer and provider of remote ambulatory cardiac monitoring and digital health solutions, announced today the appointment of Kevin Hykes as President and Chief Executive Officer, effective August 31, 2020 . Hykes will also become a member of BardyDx's Board of Directors. With over 28

• Bardy Diagnostics® Announces CE Mark Certification for 14-Day Carnation® Ambulatory Monitor (CAM®) Patch in Europe and Expansion of Home Enrollment Program Amidst COVID-19 Crisis

  5/26/2020

  Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received CE mark certification for the 14-Day version of the Carnation Ambulatory Monitor ("CAM") patch, the industry's only P-wave centric ambulatory cardiac patch monitor and arrhythmia detectio

• Bardy Diagnostics™ Announces Use of The Carnation Ambulatory Monitor Patch to Measure QT Segments in COVID-19 Patients Using Hydroxychloroquine

  3/25/2020

  Bardy Diagnostics, Inc. announced that its Carnation Ambulatory Monitor Patch has been chosen for use in protocols to measure QT Segments in COVID-19 patients who have been prescribed Hydroxychloroquine.

• Bardy Diagnostics™ Announces Commercial Launch of the 14-Day Carnation Ambulatory Monitor (CAM) Patch

  1/23/2020

  Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today the commercial launch of the 14-Day version of the Carnation Ambulatory Monitor ("CAM™"), the industry's only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device, following recent clearance by the FDA. 

• Bardy Diagnostics™ Names Ed Vertatschitsch as Chief Operating Officer and Announces Additions to the Leadership Team

  1/13/2020

  Bardy Diagnostics, Inc.,, a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, including the Carnation Ambulatory Monitor, the only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device, announced the appointment of Ed Vertatschitsch as Chief Operating Officer effective January 2, 2020.

• Bardy Diagnostics™ Wins the Remote Monitoring in Arrhythmias Digital Health Pitch Session at European Society of Cardiology Congress 2019 and Presents at UK Heart Rhythm Congress 2019

  10/24/2019

  Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that it was selected as winner of the "Remote Monitoring in Arrhythmias" Technology and Innovation Pitch Session held as part of the Digital Health program at the European Society of Cardiology (ESC) Congress 2019. 

• Bardy Diagnostics™ Receives FDA 510(k) Clearance for 14-Day Carnation Ambulatory Monitor (CAM) Patch

  9/6/2019

  Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for the 14-Day version of the Carnation Ambulatory Monitor ("CAM™"), the industry's only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device. 

• Bardy Diagnostics™ Selected As Finalist For Two MedTech Insight Awards To Be Announced At AdvaMed's Annual MedTech Conference

  8/19/2019

  Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that Informa Pharma Intelligence, a leading international healthcare intelligence consultancy, has recognized BardyDx as a finalist in two categories for the 2nd Annual Medtech Insight Awards for "Best Technical Innovation: Diagnostics" and "Best Proof-of-Value of an Innovation". 

• Bardy Diagnostics™ Selected as One of Six Disruptive MedTech Startups For the HealthTech Arkansas Accelerator Program

  8/9/2019

  Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that HealthTech Arkansas, a healthcare accelerator and investment fund that connects early-stage healthcare companies with disruptive technologies to Arkansas healthcare providers, has selected BardyDx to participate in the organization's 2019 accelerator program.

• Bardy Diagnostics™ Selected as One of 50 Leading Startups in the 2019 MedTech Innovator Showcase Program

  6/19/2019

  Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that MedTech Innovator, the premier nonprofit startup accelerator in the medical technology industry, has selected BardyDx to participate in the organization's 2019 Showcase program, featuring the most promising medical technologies from around the globe

• Bardy Diagnostics™ Announces $35.5M in Series B Funding Round

  4/16/2019

  Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has raised $35.5 million in Series B funding

• Bardy Diagnostics™ Selected as Winner of The Impact Pediatric Health Competition At SXSW 2019

  3/26/2019

  Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, including the Carnation Ambulatory Monitor ("CAM™"), the industry's first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device, announced it has been selected as one of four winners of the Impact Pediatric Health Competition held at SXSW 2019

• Bardy Diagnostics™ Announces Expansion into Canadian Market with Distributor JNC Medical

  2/28/2019

  The agreement grants JNC Medical the right to distribute the BardyDx Carnation Ambulatory Monitor, the industry's first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device, in the Canadian market.

• Bardy Diagnostics™ awarded Innovative Technology Contract with Vizient, Inc. for the Carnation Ambulatory Monitor™

  10/11/2018

  Bardy Diagnostics, Inc. announced today it was awarded an Innovative Technology contract with Vizient, Inc. for the Carnation Ambulatory Monitor

• Bardy Diagnostics™ Selected as a Winner of the Children's National Pediatric Medical Device Innovation Competition

  9/26/2018

  Bardy Diagnostics, Inc. announced it was selected as one of six winners of the "Make Your Medical Device Pitch for Kids!" Competition hosted by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System.

• Bardy Diagnostics™ Announces Additional Growth Capital Funding

  7/16/2018

  Bardy Diagnostics, Inc. announced it has raised additional growth capital from its existing equity investors, including SV Health Investors ("SVHI"), Health Enterprise Partners, and Ascension Ventures.

• Bardy Diagnostics™ Announces Validation of AI-Enabled Automatic Screening Technology for Atrial Fibrillation

  5/9/2018

  Bardy Diagnostics, Inc. is the provider of the world's only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device

• Bardy Diagnostics™ Announces Appointment of Alan Levy to Board of Directors

  4/24/2018

  Bardy is a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, including the Carnation Ambulatory Monitor ("CAM™"), the world's only P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device